doi:10.3969/j.issn.1004-583X.2024.11.012

Abstract

CLC Number:

R574

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.11.012

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I11/1035

References 31

[1]	Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment[J]. World J Gastroenterol, 2018, 24(35):4014-4020.
[2]	Mohamed MFH, Marino D, Elfert K, et al. Dye chromoendoscopy outperforms high-definition white light endoscopy in dysplasia detection for patients with inflammatory bowel disease: An updated meta-analysis of randomized controlled trials[J]. Am J Gastroenterol, 2024, 119(4):719-726. doi: 10.14309/ajg.0000000000002595 pmid: 38038351
[3]	Coelho-Prabhu N, Lewis JD. Update on endoscopic dysplasia surveillance in inflammatory bowel disease[J]. Am J Gastroenterol, 2023, 118(10):1748-1755.
[4]	Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031 pmid: 33359090
[5]	Maida M, Morreale GC, Sferrazza S, et al. Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases[J]. Dig Liver Dis, 2021, 53(9):1171-1177.
[6]	Kumar A, Shenoy V, Buckley MC, et al. Endoscopic disease activity and biologic therapy are independent predictors of suboptimal bowel preparation in patients with inflammatory bowel disease undergoing colonoscopy[J]. Dig Dis Sci, 2022, 67(10):4851-4865.
[7]	Dai C, Tian W, Huang YH, et al. Effectiveness of 4 L, 2 L, and 1 L PEG bowel preparation for colonoscopy in patients with ulcerative colitis: A retrospective study[J]. Rev Esp Enferm Dig, 2023.
[8]	Hassan C, East J, Radaelli F, et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Update 2019[J]. Endoscopy, 2019, 51(8):775-794.
[9]	Buisson A, Gonzalez F, Poullenot F, et al. Comparative acceptability and perceived clinical utility of monitoring tools: A nationwide survey of patients with inflammatory bowel disease[J]. Inflamm Bowel Dis, 2017, 23(8):1425-1433. doi: 10.1097/MIB.0000000000001140 pmid: 28570431
[10]	Te Groen M, Derks M, den Broeder N, et al. Quality of surveillance impacts the colitis-associated advanced neoplasia risk: A multicenter case-control study[J]. Clin Gastroenterol Hepatol, 2024, 22(2):357-367.
[11]	Wijnands AM, Te Groen M, Peters Y, et al. Patients prioritize a low-volume bowel preparation in colitis-associated colorectal cancer surveillance: A discrete choice experiment[J]. Inflamm Bowel Dis, 2022, 28(7):1053-1060.
[12]	Belvis Jiménez M, Hergueta-Delgado P, Gómez Rodríguez BJ, et al. Index of the mayo endoscopy and ulcerative colitis endoscopy index of severity: Are they equally valid?[J] Rev Esp Enferm Dig, 2020, 112(11):821-825. doi: 10.17235/reed.2020.6832/2019 pmid: 33054301
[13]	Elford AT, Hirsch R, McKay OM, et al. Identifying the real-world challenges of dysplasia surveillance in inflammatory bowel disease: A retrospective cohort study in a tertiary health network[J]. Intern Med J, 2024, 54(1):96-103.
[14]	Santi G, Michetti P, Froehlich F, et al. Adherence to recommendations and quality of endoscopic colorectal cancer surveillance in long-standing ulcerative colitis[J]. Inflamm Bowel Dis, 2021, 6(1):25-31.
[15]	中国医师协会内镜医师分会消化内镜专业委员会, 中国抗癌协会肿瘤内镜学专业委员会. 中国消化内镜诊疗相关肠道准备指南(2019, 上海)[J]. 中华内科杂志, 2019, 58(7):485-495.
[16]	Hashimoto Y, Kuribayashi S, Itoi Y, et al. Safety of full bowel preparation and colonoscopy in elderly patients with ulcerative colitis: A real-world multicenter retrospective cohort study[J]. DEN Open, 2024, 4(1):e275.
[17]	Burnett-Hartman AN, Hua X, Rue TC, et al. Risk interval analysis of emergency room visits following colonoscopy in patients with inflammatory bowel disease[J]. PLoS One, 2019, 14(1):e0210262.
[18]	Rejchrt S, Bures J, Siroký M, et al. A prospective, observational study of colonic mucosal abnormalities associated with orally administered sodium phosphate for colon cleansing before colonoscopy[J]. Gastrointest Endosc, 2004, 59(6):651-654. pmid: 15114307
[19]	Restellini S, Kherad O, Bessissow T, et al. Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease[J]. World J Gastroenterol, 2017, 23(32):5994-6002.
[20]	Bezzio C, Schettino M, Manes G, et al. Tolerability of bowel preparation and colonoscopy in IBD patients: results from a prospective, single-center, case-control study[J]. Crohns Colitis 360, 2020, 2(4):otaa077.
[21]	Neri B, Scarozza P, Giannarelli D, et al. Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases[J]. Eur J Gastroenterol Hepatol, 2021, 33(7):977-982.
[22]	Kim KO, Kim EY, Lee YJ, et al. Efficacy, safety and tolerability of oral sulphate tablet for bowel preparation in patients with inflammatory bowel disease: A multicentre randomized controlled study[J]. J Crohns Colitis, 2022, 16(11):1706-1713.
[23]	Lee JM, Lee KM, Kang HS, et al. Oral sulfate solution is as effective as polyethylene glycol with ascorbic acid in a split method for bowel preparation in patients with inactive ulcerative colitis: A randomized, multicenter, and single-blind clinical trial[J]. Gut Liver, 2023, 17(4):591-599. doi: 10.5009/gnl220202 pmid: 36588527
[24]	Briot C, Faure P, Parmentier AL, et al. Efficacy, tolerability, and safety of low-volume bowel preparations for patients with inflammatory bowel diseases: The French multicentre CLEAN study[J]. J Crohns Colitis, 2019, 13(9):1121-1130. doi: 10.1093/ecco-jcc/jjz040 pmid: 30785181
[25]	Rueda García JL, Suárez Ferrer C, Martín-Arranz E, et al. Randomized clinical trial evaluating three low-volume preparations for colonoscopy in outpatients with inflammatory bowel disease: the EII-PREP trial[J]. Scand J Gastroenterol, 2023, 58(6):656-663.
[26]	Mohsen W, Williams AJ, Wark G, et al. Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: Does underlying inflammatory bowel disease impact tolerability and efficacy?[J] World J Gastroenterol, 2021, 27(11):1090-1100.
[27]	Bacsur P, Rutka M, Asbóth A, et al. Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls[J]. Therap Adv Gastroenterol, 2023, 16:17562848231174298.
[28]	Powles STR, Gallagher KI, Chong LWL, et al. Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome[J]. BMC Gastroenterol, 2022, 22(1):240. doi: 10.1186/s12876-022-02301-1 pmid: 35562657
[29]	Gajera A, South C, Cronley KM, et al. High-volume colonic lavage is a safe and preferred colonoscopy preparation for patients with inflammatory bowel disease[J]. Crohns Colitis 360, 2022, 4(3):otac024.
[30]	Megna B, Weiss J, Ley D, et al. Clear liquid diet before bowel preparation predicts successful chromoendoscopy in patients with inflammatory bowel disease[J]. Gastrointest Endosc, 2019, 89(2):373-379.
[31]	Maratt JK, Siegel CA, Barkun AN, et al. An expert consensus to standardize assessment of bowel cleansing for clinical trials of bowel preparations for Crohn's disease[J]. Dig Dis Sci, 2023, 68(5):1718-1727.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Gu Dandan, Zhou Xiaoxian, Wang Jingxian, Wu Chunxiao. Rectal cap polyposis: A case report and literature review [J]. Clinical Focus, 2024, 39(9): 828-832.
[2]	Chen Xiaotian, Huo Lijuan. Predictive value of serum total bilirubin, neutrophil-to-total bilirubin ratio in evaluating the condition of ulcerative colitis [J]. Clinical Focus, 2024, 39(7): 603-611.
[3]	Ren Huaijing, Tao Jianan, Ma Zhenqi, Wang Xuehong. Colonic telangiectasia combined with bleeding: A case report and literature review [J]. Clinical Focus, 2024, 39(2): 155-159.
[4]	Chen Xiaotian, Huo Lijuan. Meta-analysis of clinical significance of serum total bilirubin level in inflammatory bowel disease [J]. Clinical Focus, 2023, 38(8): 677-685.
[5]	Li Lifang, Wang Hongyan. Respiratory Whipple's disease: A case report and literature review [J]. Clinical Focus, 2022, 37(12): 1127-1131.
[6]	Zhang Xiumin, Zhao Changdong, Li Xue, Lu Xuefeng, Liu Weizhong, Wang Shufang. Relationship between indoleamine 2, 3-dioxygenase and peripheral blood CD4 + in patients with ulcerative colitis [J]. Clinical Focus, 2021, 36(8): 696-698.
[7]	Song Yiran, Liang Xiaonan, Li Chenyang, Zhang Xiaolan. Interpretation on Chinese Expert Consensus of Irritable Bowel Syndrome in 2020 [J]. Clinical Focus, 2021, 36(7): 628-631.
[8]	. [J]. Clinical Focus, 2021, 36(5): 467-470.
[9]	Wang Tingting, Wang Liangzhi. Expression and clinical significance of apolipoprotein M in inflammatory bowel disease [J]. Clinical Focus, 2016, 31(1): 53-55.
[10]	Guo Wenbin,Sun Ximing. Clinical effect of pernasal catheter in adhesive intestinal obstruction [J]. Clinical Focus, 2016, 31(1): 85-87.
[11]	. [J]. Clinical Focus, 2015, 30(9): 1056-1059.
[12]	. @@ [J]. Clinical Focus, 2014, 29(12): 1401-0.
[13]	. @@ [J]. Clinical Focus, 2014, 29(12): 1429-1431.
[14]	ZHENG Xiu-li;FU Xue-song;WANG Yu-gang;ZHANG Yan-hua;ZHAO Xia;LI Hong-yin. Effect of otilonium bromide combined with probiotics for diarrhea-predominant irritable bowel syndrome [J]. Clinical Focus, 2014, 29(10): 1168-1170.
[15]	. [J]. Clinical Focus, 2014, 29(9): 1055-1056.